Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (351-360 of 398) with videos related to

Pageof 40
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2010
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imagingEmilio Bombardieri, Francesco Giammarile, Cumali Aktolun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 PatientsElse A Aalbersberg, Daphne M V Huizing, Iris Walraven, et al.
Clinical & Experimental Metastasis|August 8, 2014
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasmD Kaemmerer, N Posorski, F von Eggeling, et al.
Oncotarget|April 24, 2018
Results and adverse events of personalized peptide receptor radionuclide therapy with <sup>90</sup>Yttrium and <sup>177</sup>Lutetium in 1048 patients with neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Aviral Singh, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 8, 2016
<sup>64</sup>Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human StudiesBernhard Grubmüller, Richard P Baum, Enza Capasso, et al.
Seminars in Nuclear Medicine|September 1, 2019
From Bench to Bedside-The Bad Berka Experience With First-in-Human StudiesJingjing Zhang, Aviral Singh, Harshad R Kulkarni, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-upDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Cancers|February 13, 2025
Long-Term Safety and Survival Outcomes of [<sup>225</sup>Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [<sup>225</sup>Ac]Ac-/[<sup>177</sup>Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate CancerElisabetta Perrone, Alessandro Giordano, Maria Lucia Calcagni, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
Pageof 40

Showing results (351-360 of 398) with videos related to

Sort By:
Pageof 40
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2010
131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imagingEmilio Bombardieri, Francesco Giammarile, Cumali Aktolun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 PatientsElse A Aalbersberg, Daphne M V Huizing, Iris Walraven, et al.
Clinical & Experimental Metastasis|August 8, 2014
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasmD Kaemmerer, N Posorski, F von Eggeling, et al.
Oncotarget|April 24, 2018
Results and adverse events of personalized peptide receptor radionuclide therapy with <sup>90</sup>Yttrium and <sup>177</sup>Lutetium in 1048 patients with neuroendocrine neoplasmsRichard P Baum, Harshad R Kulkarni, Aviral Singh, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 8, 2016
<sup>64</sup>Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human StudiesBernhard Grubmüller, Richard P Baum, Enza Capasso, et al.
Seminars in Nuclear Medicine|September 1, 2019
From Bench to Bedside-The Bad Berka Experience With First-in-Human StudiesJingjing Zhang, Aviral Singh, Harshad R Kulkarni, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-upDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Cancers|February 13, 2025
Long-Term Safety and Survival Outcomes of [<sup>225</sup>Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [<sup>225</sup>Ac]Ac-/[<sup>177</sup>Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate CancerElisabetta Perrone, Alessandro Giordano, Maria Lucia Calcagni, et al.
Journal of Neuroendocrinology|November 8, 2025
Systematic review and meta-analysis of the efficacy and safety of [<sup>177</sup>Lu]Lu-edotreotide ([<sup>177</sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumorsRichard P Baum, Julia G Fricke, Tristan Ruhwedel, et al.
Pageof 40